intranasal subunit vaccine (STING agonist adjuvant) (AuraVax Therapeutics/University of Houston)

N/A

Report date: 2025/01/26 19:21:41

Base Information

Drug Nameintranasal subunit vaccine (STING agonist adjuvant) (AuraVax Therapeutics/University of Houston)
Drug Alias Nameprotein subunit vaccine (AuraVax Therapeutics/University of Houston)SARS-CoV-2 vaccine (AuraVax Therapeutics/University of Houston)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionStimulator of interferon genes stimulants
TargetsStimulator of interferon genes
Therapy Area/IndicationsCoronavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAuraVax Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of HoustonAuraVax Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A